How do I find reliable early-stage therapeutic biotech blogs for small-molecule discovery updates?

A good way to find reliable early-stage therapeutic biotech blogs focused on small-molecule discovery is to use a mix of source filtering, topic-specific search, and credibility checks.

1) Start with the right types of sources

Look for blogs or update pages from:

• Small biotech companies doing drug discovery
• Venture studios / incubators in therapeutics
• CROs and assay vendors that publish technical notes
• Academic labs with translational chemistry focus
• Industry analysts covering discovery-stage biotech
• Conference recap blogs from reputable life science groups

For small-molecule discovery, useful topic keywords include:

• hit identification
• lead optimization
• medicinal chemistry
• fragment-based drug discovery
• structure-based drug design
• assays / screening
• ADMET / DMPK
• target validation
• chemical biology

2) Use targeted searches

Try search queries like:

• site:companydomain.com blog medicinal chemistry small molecule discovery
• site:*.com "lead optimization" biotech blog
• site:*.org therapeutic biotech small molecule blog
• "fragment-based drug discovery" blog biotech
• "small molecule" "discovery" "blog" biotech
• "medicinal chemistry" "updates" biotech

You can also search on:

• Google News
• LinkedIn posts from biotech founders/scientists
• X/Twitter for research staff or company announcements
• Substack or Medium if you want commentary, though these require more filtering

3) Check whether the source is actually reliable

A good blog should have:

• Named authors with real scientific credentials
• Clear affiliation to a company, lab, or institution
• Primary-data references: papers, posters, patents, preprints, conference abstracts
• Specificity: mentions targets, assays, compound classes, or screening methods
• Consistency over time
• No exaggerated claims like “breakthrough cure” or “guaranteed first-in-class”

Red flags:

• Anonymous authors
• Vague, hype-heavy language
• No references
• Overstated clinical conclusions from early discovery data
• Heavy promotion with little technical content

4) Prefer sources that connect to primary evidence

For early-stage discovery, the best blog posts often cite:

• PubMed papers
• bioRxiv / medRxiv preprints
• patents
• conference posters
• company press releases with scientific detail
• investor decks that include target and chemistry specifics

If the blog only repeats press releases without technical depth, it’s less useful.

5) Build a curated watchlist

Create a shortlist using:

• RSS feeds
• Google Alerts
• LinkedIn company pages
• Subscriptions to biotech newsletters
• Patent alert tools for target names or scaffold families

A simple watchlist structure:

• Company / blog name
• Focus area
• Target class
• Evidence level
• Update frequency
• Notes on credibility

6) Use community and expert filters

Good places to discover trustworthy biotech blogs:

• Biopharma newsletters
• Conference speaker lists
• MedChem and drug discovery communities
• Journalistic roundups from reputable industry outlets
• Academic and industry podcast show notes

If a blog is frequently cited by scientists, analysts, or patent/medchem communities, that’s a strong sign.

7) If you want “reliable,” define the use case

Different “reliable” standards apply depending on what you need:

• Commercial intelligence: prioritize company updates, patents, and investor materials
• Scientific tracking: prioritize posts with data, references, and methods
• Trend spotting: broader industry blogs are fine, but verify claims elsewhere

Quick practical workflow

1. Search for blogs with your target keywords.
2. Filter for named authors and scientific affiliations.
3. Check whether posts cite papers, patents, or posters.
4. Cross-check claims against PubMed, patents, and company announcements.
5. Add the best ones to an RSS/news alert system.

If you want, I can also give you:

• a curated list of reputable biotech/discovery blogs, or
• a search strategy specific to a target area like kinase inhibitors, oncology, CNS, or protein degraders.